2025-521973-16-00招募中2 期
A PHASE 1/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF SINGLE AND MULTIPLE ASCENDING DOSES OF BCX17725 IN HEALTHY PARTICIPANTS AND MULTIPLE DOSES OF BCX17725 IN PARTICIPANTS WITH NETHERTON SYNDROME
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 2
- 试验地点
- 2
- 主要终点
- Effectiveness : Primary Effectiveness Endpoint: • Change from baseline in Ichthyosis Area and Severity Index (IASI) score at Week 12
研究概览
简要总结
Effectiveness: To evaluate the therapeutic potential of BCX17725 in adult and adolescent participants with NS. Safety: To evaluate the safety and tolerability of BCX17725 when administered for 12 weeks in adult and adolescent participants with NS. PK:To characterize BCX17725 concentrations in serum of adult and adolescent participants with NS.
研究设计
- 分配方式
- Not Applicable
- 主要目的
- 1
- 盲法
- None
入排标准
- 年龄范围
- 0 years 至 64 years（0-17 Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Able to provide written informed consent. Adolescent participants should provide assent (age determined by applicable institutional policy) with parent/legal guardian consent.
- •Male or non-pregnant, non-lactating female, aged 12 to 65 years, inclusive, with a confirmed diagnosis of NS. Note: Participants without pre-existing documentation of SPINK5 gene variant(s) confirming NS diagnosis will be required to provide a blood sample for genetic testing at screening.
- •IGA score ≥ 3 and an IASI score of ≥ 16 at screening and Day 1 (baseline).
- •Females of childbearing potential and males with female partners of childbearing potential, must agree to follow the contraception requirements outlined in Section 5.3 of the protocol from screening until 90 days after the last dose of BCX
- •Participant (or, where applicable, parent/legal guardian) is willing and able to understand and comply with all applicable study requirements, including:a.a. Available to complete the entire study duration; b: Able to understand the study procedures including the ability to complete any self assessment questionnaires or instruments; c: Willing to have skin strip samples collected
排除标准
- •Apart from a diagnosis of NS, any clinically significant disease or condition (eg, medical, psychiatric, or social) that, in the opinion of the investigator, would interfere with the participant’s ability to participate in the study or increase the risk of participation for that participant.
- •Any abnormal laboratory parameter at screening or Day 1 that, in the opinion of the investigator, is clinically significant and relevant for this study, including but not limited to those listed below. Enrollment of a participant with a laboratory value outside of the reference range may be permissible if the abnormality is documented by the investigator not to be of clinical significance. a. AST, ALT, or total bilirubin value > 1.5 × ULN b. Platelet count < 150,000/µL
- •History of anaphylaxis or other severe reaction to any biologic or protein therapeutic agent, which, in the opinion of the investigator or sponsor medical monitor, should contraindicate their participation in this study.
- •History of sensitivity to any component of the IMP.
- •Receipt of any investigational drug, systemic biologic, or systemic immunoglobulin within 8 weeks prior to Day 1 or anticipated receipt during the study (excluding potential receipt of BCX17725 during the study). Note: Individuals who participate in Part 3 may additionally participate in Part 4, providing they meet all applicable eligibility criteria for Part 4 and experienced no significant safety concerns related to BCX17725 administration in Part
- •Part 3 participants qualifying for Part 4 enrollment will be subject to the washout period as described above
- •Use of systemic retinoids, other systemic immunosuppressants, systemic corticosteroids, or phototherapy within 4 weeks prior to Day 1 or anticipated use during the study.
- •Use of ultra-high to medium potency topical corticosteroids (WHO Classes 1 to 5 or equivalent; see Appendix 3) within 2 weeks prior to Day 1 or anticipated use during the study.
- •Participant is pregnant, planning to become pregnant, or having been pregnant within 90 days before Day 1, or lactating.
- •Any other skin disease that may interfere with planned NS skin evaluations.
- •Any infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, or antifungals within 2 weeks prior to Day
- •History of malignancy within 5 years prior to screening, with exception of adequately treated non-melanoma skin or superficial bladder cancer, curatively treated carcinoma in situ of the cervix, or other curatively treated solid tumor deemed by the investigator and medical monitor to be at low risk for recurrence.
- •Any clinically significant history of a cardiovascular abnormality, including but not limited to angina, known coronary artery disease, myocardial infarction, clinically significant cardiac arrhythmias, left ventricular hypertrophy, cardiomyopathy, or aortic stenosis.
- •History of significant drug or alcohol abuse in the 6 months prior to screening or a positive drugs of abuse screen (not supported by a legitimate prescription) at screening.
- •Positive test result for HIV at screening.
- •Active hepatitis B virus infection, determined by positive test result for hepatitis B surface antigen, at screening.
- •Active hepatitis C infection, determined as HCV RNA above the limit of detection in participants with positive HCV antibody titer, at screening.
结局指标
主要结局
Effectiveness : Primary Effectiveness Endpoint: • Change from baseline in Ichthyosis Area and Severity Index (IASI) score at Week 12
Effectiveness : Primary Effectiveness Endpoint: • Change from baseline in Ichthyosis Area and Severity Index (IASI) score at Week 12
Safety : Incidence of TEAEs through End-of-Study (EOS)
Safety : Incidence of TEAEs through End-of-Study (EOS)
PK : Concentration of BCX17725 in serum through EOS
PK : Concentration of BCX17725 in serum through EOS
次要结局
- Effectiveness : Key Secondary Effectiveness Endpoints: • Change from baseline in Investigator Global Assessment (IGA) score at Week 12 Change from baseline in the Worst Itch Numerical Rating Scale (NRS) score at Week 12
研究者
Study Director, BioCryst Pharmaceuticals Inc.
Scientific
Biocryst Pharmaceuticals Inc.
研究点 (2)
Loading locations...
相似试验
招募中
1 期
JY232(JY232) Injection in Relapsed/Refractory Multiple MyelomaMultiple MyelomaNCT07336823Shenzhen Genocury Biotech Co., Ltd.9
招募中
1 期
A Phase 1b study to evaluate the safety, pharmacokinetics, and anti-tumour activity of the Myc inhibitor OMO-103 administered intravenously in combination with different drugs in patients with advanced solid tumours2023-504376-21-00Peptomyc S.L.30
已完成
2 期
Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid TumorsRenal Cell CarcinomaNon-Small Cell Lung Cancer2022-500694-14-00Beigene Ltd., Beigene Ltd.48
招募中
2 期
A Phase 1/2a, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778 in Healthy Volunteers and in Subjects with Chronic Hepatitis B Infection, Including Subjects with Chronic Hepatitis D Infection2022-502724-46-00Bluejay Therapeutics Inc.16
招募中
3 期
An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis2022-502361-15-00Bristol Myers Squibb International Corporation664